Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Internal Medicine
•
Hematology
Is there a role at this time for chemo-immunotherapy in the upfront treatment of classic Hodgkin lymphoma?
Although not approved, for example, are you every using AVD-nivolumab?
Related Questions
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
What is the optimal choice of therapy for a patient with Hodgkin variant of Richter's transformation from underlying CLL/SLL?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?